Brazilian hospital adopts Lunit's AI chest X-ray solution

By Kim Joo-heon Posted : December 19, 2022, 10:23 Updated : July 21, 2023, 20:52

[Courtesy of Lunit]

SEOUL -- "Lunit INSIGHT CXR," a chest X-ray analysis solution developed by South Korea's medical artificial intelligence company Lunit, was adopted by one of the largest hospitals in Brazil to detect various types of chest diseases such as lung cancer and tuberculosis. Starting with Brazil, Lunit aims to secure its foothold in the South American medical market. 
Lunit's AI-based solution uses software robots to compare and analyze X-rays and medical images of chest disease patients and healthy people. When the solution detects an anomaly, human supervisors are notified of the situation and the patient would take extra tests. The solution was adopted by Cathay Life Insurance, a major life insurance company in Taiwan, after verifying the analysis software is capable of detecting lung cancer and unusual lesions with an accuracy rate of more than 90 percent.
Lunit said in a statement that the X-ray analysis solution will be provided to Albert Einstein Israelite Hospital, a Sao Paulo-based multi-specialty hospital that operates three affiliated hospitals with more than 600 beds each. The solution will analyze about 40,000 chest X-ray video images every year in emergency rooms and intensive care units. "This contract will be the foothold for the South American market," Lunit CEO Suh Beom-seok said in a statement on December 19. 
Lunit has worked with many foreign companies and hospitals targeting the global diagnostic imaging market expected to reach $35 billion by 2026. In July 2022, the company signed an agreement with Bumrungrad International Hospital, a major hospital in Bangkok, to deploy Lunit INSIGHT CXR. In October 2022, SEHA, a health service company based in the United Arab Emirates, teamed up with Lunit to verify the performance of Lunit INSIGHT MMG, a solution specializing in detecting breast cancer. The Middle Eastern hospital agency will consider the adoption after verifying the performance by the end of 2022.
기사 이미지 확대 보기